Karen Bissell

Dr. Karen Bissell

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Public Health Action
Verified
Journal Article
Open access
AKAjay Kumar
Ajay Kumar
HSHemant Deepak Shewade
Hemant Deepak Shewade
JTJaya Prasad Tripathy
Jaya Prasad Tripathy
NGN. Guillerm
N. Guillerm
KTK. Tayler-Smith
K. Tayler-Smith
Anthony HarriesAnthony Harries
Anthony Harries
Setting: Structured Operational Research and Training Initiative (SORT IT) courses are well known for their output, with nearly 90% of participants completing the course and publishing in scientific journals. Objective: We assessed the impact of research papers on policy and practice that resulted from six SORT IT courses initiated between July 2012 and March 2013. Design: This was a cross-sectional study involving e-mail-based, self-administered questionnaires and telephone/skype/in-person responses from first and/or senior co-authors of course papers. A descriptive content analysis of the responses was performed and categorised into themes. Results: Of 72 participants, 63 (88%) completed the course. Course output included 81 submitted papers, of which 76 (94%) were published. Of the 81 papers assessed, 45 (55%) contributed to a change in policy and/or practice: 29 contributed to government policy/practice change (20 at national, 4 at subnational and 5 at hospital level), 11 to non-government organisational policy change and 5 to reinforcing existing policy. The changes ranged from modifications of monitoring and evaluation tools, to redrafting of national guidelines, to scaling up existing policies. Conclusion: More than half of the SORT IT course papers contributed to a change in policy and/or practice. Future assessments should include more robust and independent verification of the reported change(s) with all stakeholders.

1 January 2014 in Journal of Tropical Medicine
Verified
Journal Article
Open access
PDF file
KNKeshni Naidu
Keshni Naidu
INIlisapeci Nabose
Ilisapeci Nabose
SRSharan Ram
Sharan Ram
KVKerri Viney
Kerri Viney
Steve GrahamSteve Graham
Steve Graham
KBKaren Bissell
Karen Bissell
Nosocomial infections in an intensive care unit (ICU) are common and associated with a high mortality but there are no published data from the Oceania region. A retrospective study in Fiji’s largest ICU (2011-12) reported that 114 of a total 663 adult ICU admissions had bacteriological culture-confirmed nosocomial infection. The commonest sites of infection were respiratory and bloodstream. Gram negative bacteria were the commonest pathogens isolated, especiallyKlebsiella pneumoniae(extended-spectrumβ-Lactamase-producing),Acinetobacter,andPseudomonasspecies. Mortality for those with a known outcome was 33%. Improved surveillance and implementation of effective preventive interventions are needed.

KBKaren Bissell
Karen Bissell
PEPhilippa Ellwood
Philippa Ellwood
EEEamon Ellwood
Eamon Ellwood
CCChen-Yuan Chiang
Chen-Yuan Chiang
GMGuy Marks
Guy Marks
TGthe Global Asthma Network Study Group
the Global Asthma Network Study Group
Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.

1 August 2014 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Open access
Philip HillPhilip Hill
Philip Hill
CDChristopher Dye
Christopher Dye
KVKerri Viney
Kerri Viney
KTK. Tabutoa
K. Tabutoa
TKT. Kienene
T. Kienene
Anthony HarriesAnthony Harries
Anthony Harries
SETTING: The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence. OBJECTIVE: To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati. METHODS: We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. RESULTS: Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of 90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. CONCLUSION: Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.

27 October 2014 in Journal of Tropical Medicine
Verified
Journal Article
Open access
PDF file
DBDashika A. Balak
Dashika A. Balak
KBKaren Bissell
Karen Bissell
CRChristine Roseveare
Christine Roseveare
SRSharan Ram
Sharan Ram
RDRachel R. Devi
Rachel R. Devi
Steve GrahamSteve Graham
Steve Graham
Introduction. An absolute lymphocyte count is commonly used as an alternative to a CD4 count to determine initiation of antiretroviral therapy for HIV-infected individuals in Fiji when a CD4 count is unavailable.Methods. We conducted a retrospective analysis of laboratory results of HIV-infected individuals registered at all HIV clinics in Fiji.Results. Paired absolute lymphocyte and CD4 counts were available for 101 HIV-infected individuals, and 96% had a CD4 count of ≤500 cells/mm3. Correlation between the counts in individuals was poor (Spearman rank correlationr=0.5). No absolute lymphocyte count could be determined in this population as a suitable surrogate for a CD4 count of either 350 cells/mm3 or 500 cells/mm3. The currently used absolute lymphocyte count of ≤2300 cells/μL had a positive predictive value of 87% but a negative predictive value of only 17% for a CD4 of ≤350 cells/mm3and if used as a surrogate for a CD4 of ≤500 cells/mm3it would result in all HIV-infected individuals receiving ART including those not yet eligible. Weight, CD4 count, and absolute lymphocyte count increased significantly at 3 months following ART initiation.Conclusions. Our findings do not support the use of absolute lymphocyte count to determine antiretroviral therapy initiation in Fiji.

1 June 2014 in Public Health Action
Verified
Journal Article
Open access
LFL. Fonua
L. Fonua
KBKaren Bissell
Karen Bissell
PVP. Vivili
P. Vivili
SGS. Gounder
S. Gounder
Philip HillPhilip Hill
Philip Hill
Setting: The National Tuberculosis Programme and the National Reference Laboratory, located on the main island of Tonga, Tongatapu, and three district hospital laboratories located on the outer islands. Objectives: To compare Tongatapu with Tonga's outer islands with respect to sputum referral rates, numbers of samples per patient, sample quality, test results and time from sending sample to obtaining results and from obtaining results to treatment initiation. Design: Retrospective study involving record review of laboratory and TB treatment registers in Tonga's four hospitals from 2003 to 2012. Results: Of 3078 sputum samples submitted, 71.7% were of good quality. Sputum referral rates on Tongatupu were nearly twice as high as those on the outer islands (353 vs. 180 per 100 000 population). The mean smear turnaround times on Tongatapu and the outer islands were respectively 4.02 and 4.11 days. Of 83 positive cases, 91.2% were treated within a day in Tongatapu compared with 80% in the outer islands. Conclusions: Referral rates for sputum smear testing differed in the main and the outer islands in Tonga, but turnaround times did not. Records of sputum quality and dates had limitations, necessitating interventions with TB-specific laboratory guidelines and registers. Further research is required to understand the differences in referral rates.